| VTGN Snapshot | |
|---|---|
| VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing and commercializing several drugs with the potential to treat anxiety, depression, and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California. | |
| VALUATION DATA | |
| Market Capitalization | $124,451,000 | Price to Sales | 0.00 |
| Earnings per Share | $-2.9600 |
| PE Ratio | None |
| PRICE DATA | |
| Most Recent Close | $4.6600 |
| 52 Week High | $126.79 |
| 52 Week Low | $1.076 |
| 50-Day Moving Average | $8.05 |
| 200-Day Moving Average | $-0.252 |
| All data are from Alpha Vantage as of today. For more infomation on VTGN see Stock Dividend, Valuation, Price and Financial Data for Investors | |
Custom Search